Accendra Health Inc. Common Stock (ACH)

FairStock Score: 30/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable competitive advantages, conservative balance sheets, and consistent cash generation. Accendra Health is an in-home healthcare distributor with 6,500 employees, serving diabetes, respiratory, and sleep apnea patients. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $613.2 million and net income was negative $89.1 million, or diluted EPS of negative $1.16. That was an improvement from fiscal Q2 2025, when revenue was $681.9 million and net income was negative $869.1 million, or diluted EPS of negative $11.30, but the business is still losing money and shrinking. For FY2025, ended 2025-12-31, revenue was $2.8 billion and net income was negative $1.1 billion, or diluted EPS of negative $14.31. FY2024 net loss was $362.7 million, and FY2023 net loss was $41.3 million, so the losses have grown, not shrunk. FairStock labels it a TURNAROUND — Loss in the latest year after earlier profits. The moat looks thin: medical distribution and home care are competitive and reimbursement-sensitive, and trailing free cash flow is negative $365.6 million. At the 2026-10-13 close of $0.32, FairStock calculates a P/E of negative 0.22, ROE of negative 198.35%, ROCE of 0.64%, FCF yield of negative 1485.6%, Piotroski of 3/9, and Altman Z-Score of negative 0.68. Market cap is $24.6 million. A low price against a $2.8 billion revenue base may look tempting, but negative cash flow and distress ratios suggest the equity is speculative. I would need evidence of stabilizing revenue, positive cash generation, and a stronger balance sheet before calling it a sound value.

In plain English: Accendra Health provides home health care products and services, including diabetes supplies, breathing therapy, and sleep apnea devices. The business is losing money, sales are falling, and it is burning cash. At 32 cents a share, the price may look low, but the numbers show a troubled company rather than a clearly cheap one.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer